MedTrace Logo

Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

NCT00112229 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2013-04-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety of this vaccination.

Conditions

Interventions

BIOLOGICAL

group 1

Melan-A analog peptide + CpG + Montanide

BIOLOGICAL

group 2

Melan-A natural peptide + CpG + Montanide

BIOLOGICAL

group 3

Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide

BIOLOGICAL

group 4

Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide

Sponsors & Collaborators

  • Ludwig Institute for Cancer Research

    collaborator OTHER

  • Centre Hospitalier Universitaire Vaudois

    lead OTHER

Principal Investigators

  • Olivier Michielin, MD · Ludwig Institute for Cancer Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2011-08-31
Completion
2012-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00112229 on ClinicalTrials.gov